PIEZO1 and non-small cell lung carcinoma: Piezo1 inhibition leads to increased cell migration in non-small cell lung carcinoma (Huang et al., 2019) and breast cancer (Yu et al., 2020) but decreased cell migration in gastric cancer (Zhang et al., 2018) and glioma (Chen et al., 2018).